Sean Richardson – GM, Alexion Pharma UK
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
Address: First Floor, Building 2,
Croxley Green Business Park,
Marlins Meadows
Watford, Hertfordshire
United Kingdom – WD18 8YA
Tel: +44 (0) 1923 202 950
Web: http://eu.glenmark-generics.com/
Glenmark Generics (Europe) Ltd headquartered in the UK operates through its own sales infrastructure in the UK and through licensing & distribution arrangements in other European markets.
The UK office based in Hatfield, Hertfordshire possesses the infrastructure to support licensing, regulatory submissions, project management, distribution of sales in the UK and across Europe.
Glenmark is building its presence in markets across Europe and seeks out opportunities to develop strategic alliances and marketing collaborations with leading generic companies operating in the EU markets.
Glenmark was awarded the prestigious SCRIP award in 2008 for the Best Pharma company in the world – SME & the Best Company in Emerging Markets.
Glenmark Generics (Europe) Ltd has an exciting portfolio of 5 approved products, 12 products filed and pending approval; with a further 15 products in development. These are solid and semi-solid products filed as EU CTD dossiers and offered for out-licensing to prospective partners. Most of the portfolio are backed up with vertical integration on APIs.
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
Karen Osborn, CEO of the International Glaucoma Association, explains the role of the charity, detailing its threefold purpose of funding research, raising awareness and helping patients live with the disease.…
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid…
Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and…
See our Cookie Privacy Policy Here
